Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Anthem top executive Swedish to become adviser, Boudreaux named CEO

Published 11/06/2017, 09:26 AM
© Reuters. People enter the office building of health insurer Anthem in Los Angeles, California

(Reuters) - Anthem Inc's (N:ANTM) Joseph Swedish will be replaced as chief executive by industry veteran Gail Boudreaux but will stay on as executive chairman until May 2018 and be a senior adviser through May 2020, the health insurer said on Monday.

The Wall Street Journal first reported the news on Friday.

Swedish will continue to receive his current salary as executive chairman and be eligible for a prorated bonus and as an adviser, he will be paid $4.5 million per year.

Swedish's move comes at a time of change for Anthem, the No. 2 U.S. health insurer. The company cut Obamacare individual market participation by 70 percent for next year and recently announced plans to bring its pharmacy benefit management in house. It also may face a much larger Aetna Inc (N:AET), which is considering a deal with CVS Health Corp (N:CVS), according to sources.

Boudreaux was most recently CEO of United Healthcare, a unit of the biggest U.S. health insurer, UnitedHealth Group Inc (N:UNH). Before that, she was an executive at the next largest operator of Blue Cross Blue Shield licensed insurers, Health Care Services Corp, and at Aetna.

BMO Markets analyst Matthew Borsch said in a research note that Boudreaux is held in high regard by investors but that Anthem's stock is still a "market-perform" given the company's slower-growth business mix.

"We expect there may be a period of uncertainty among investors until the reasons for the reported leadership change are understood and fully accepted by the market," he wrote.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Boudreaux, who will take on the role of CEO on Nov. 20, will receive an annual salary of $1.4 million with a potential bonus of up to 350 percent of her salary, along with an initial stock grant worth $2 million. Long-term incentives are worth up to $10.25 million.

Swedish orchestrated Anthem's $54 billion deal for smaller rival Cigna Corp (N:CI) in 2015, which was ultimately scrapped as regulators said that and Aetna's proposed acquisition of Humana Inc (N:HUM) would be anti-competitive.

Two weeks ago, news broke that Aetna and CVS were in talks over a deal that would create a combined health insurance, pharmacy benefit management, and pharmacy company. The deal is expected in December, Reuters reported.

The impact of that deal is unclear on Anthem's recently announced plan to use CVS to help manage its pharmacy benefits business as it exits its contract with Express Scripts Holding (O:ESRX).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.